The Oncology Institute, Inc. (TOI)

US — Healthcare Sector
Peers: RMYHY  MFCSF  JNHMF  MCIOF  FSNUY  CANO  LFST  AGL  PNTG  BKD  SGRY  SEM  ENSG  MD  UHS  ADUS  EHC  CCM  AMS  SNDA  JYNT 

Automate Your Wheel Strategy on TOI

With Tiblio's Option Bot, you can configure your own wheel strategy including TOI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TOI
  • Rev/Share 0.5229
  • Book/Share 0.0066
  • PB 494.3207
  • Debt/Equity 5.6051
  • CurrentRatio 1.7941
  • ROIC -0.4941

 

  • MktCap 289880825.0
  • FreeCF/Share -0.0248
  • PFCF -15.1374
  • PE -36.8617
  • Debt/Assets 0.1732
  • DivYield 0
  • ROE -5.097

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation TOI BTIG Research -- Buy -- $7 May 15, 2025

News

The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes
TOI
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23.

Read More
image for news The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes
The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025
TOI
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024.

Read More
image for news The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025
The Oncology Institute Announces $16.5 million Private Placement
TOI
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors for a private placement that is expected to result in gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses (the “Private Placement”). The Private Placement includes participation from existing investors, as well as members of the Company's management team and Board of Directors and is expected to close …

Read More
image for news The Oncology Institute Announces $16.5 million Private Placement

About The Oncology Institute, Inc. (TOI)

  • IPO Date 2020-06-04
  • Website https://theoncologyinstitute.com
  • Industry Medical - Care Facilities
  • CEO Dr. Daniel Virnich FACHE, M.B.A., M.D.
  • Employees 825
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.